MedTrace Logo

Selegiline for Smoking Cessation - 1

NCT00439413 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2017-02-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.

Conditions

  • Nicotine Dependence

Interventions

DRUG

Selegiline Transdermal Patch

Selegiline cm(2) via transdermal system

DRUG

Placebo

Matching placebo via transdermal system

BEHAVIORAL

Smoking Cessation Counseling

Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks

Sponsors & Collaborators

  • VA Office of Research and Development

    collaborator FED

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Elbert D Glover, Ph.D. · VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-08-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439413 on ClinicalTrials.gov